• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫疗法与超进展：不良结局，机制不明。

Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.

机构信息

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, New York.

出版信息

Clin Cancer Res. 2019 Feb 1;25(3):904-906. doi: 10.1158/1078-0432.CCR-18-3144. Epub 2018 Nov 5.

DOI:10.1158/1078-0432.CCR-18-3144
PMID:30397179
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6359946/
Abstract

Hyperprogression (HP) is a recently defined clinical phenomenon in which patients treated with immunotherapy paradoxically exhibit rapid tumor growth. The mechanisms of hyperprogression remain ill-defined, although recent studies in this issue point to a possible role for Fc receptors in this process..

摘要

超进展（HP）是一种最近定义的临床现象，接受免疫治疗的患者会出现肿瘤快速生长的反常现象。超进展的机制仍不清楚，尽管本期的一些研究提示 Fc 受体可能在这一过程中发挥作用。

相似文献

1
Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.免疫疗法与超进展：不良结局，机制不明。
Clin Cancer Res. 2019 Feb 1;25(3):904-906. doi: 10.1158/1078-0432.CCR-18-3144. Epub 2018 Nov 5.
2
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.抗体 Fc/FcR 相互作用在巨噬细胞中作为 PD-1/PD-L1 阻断后非小细胞肺癌发生超进展性疾病的机制。
Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.
3
Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer.超进展-免疫治疗相关现象与癌症的内在自然史
JAMA Oncol. 2019 May 1;5(5):743. doi: 10.1001/jamaoncol.2019.0130.
4
Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply.超进展-免疫治疗相关现象与癌症的内在自然史——回应
JAMA Oncol. 2019 May 1;5(5):744. doi: 10.1001/jamaoncol.2019.0138.
5
Hyperprogression during immunotherapy: do we really want to know?免疫治疗期间的超进展：我们真的想知道吗？
Ann Oncol. 2019 Jul 1;30(7):1028-1031. doi: 10.1093/annonc/mdz184.
6
Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1.程序性死亡配体1强表达的肺腺癌患者免疫治疗后超进展的特征分析
J Thorac Oncol. 2020 Jan;15(1):e4-e8. doi: 10.1016/j.jtho.2019.08.007.
7
[Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer].[非小细胞肺癌免疫治疗生物标志物的程序性死亡配体1（PD-L1）检测的当前挑战]
Zhonghua Bing Li Xue Za Zhi. 2019 Aug 8;48(8):585-589. doi: 10.3760/cma.j.issn.0529-5807.2019.08.001.
8
Pseudoprogression and hyperprogression after checkpoint blockade.免疫检查点抑制剂治疗后的假性进展和超进展。
Int Immunopharmacol. 2018 May;58:125-135. doi: 10.1016/j.intimp.2018.03.018. Epub 2018 Mar 23.
9
Immunotherapy in non-small cell lung cancer: The past, the present, and the future.非小细胞肺癌中的免疫疗法：过去、现在与未来。
Thorac Cancer. 2019 Apr;10(4):585-586. doi: 10.1111/1759-7714.13012. Epub 2019 Feb 28.
10
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system.免疫治疗后消化系统恶性肿瘤患者的超进展。
BMC Cancer. 2019 Jul 17;19(1):705. doi: 10.1186/s12885-019-5921-9.

引用本文的文献

1
LAG-3-An incompletely understood target in cancer therapy.LAG-3——癌症治疗中一个尚未完全了解的靶点。
FASEB J. 2024 Nov 30;38(22):e70190. doi: 10.1096/fj.202401639R.
2
Thrombocytopenia and hyperprogression after radiotherapy and camrelizumab treatment in an esophageal cancer patient with increased gene copies: a case report.一名基因拷贝数增加的食管癌患者放疗和卡瑞利珠单抗治疗后出现血小板减少和超进展：一例报告
Front Oncol. 2024 Jun 21;14:1283428. doi: 10.3389/fonc.2024.1283428. eCollection 2024.
3
Single-port video-assisted thoracoscopic sleeve lobectomy after neoadjuvant immunochemotherapy: a case report.新辅助免疫化疗后单孔电视辅助胸腔镜袖式肺叶切除术：一例报告
Transl Lung Cancer Res. 2024 Feb 29;13(2):423-433. doi: 10.21037/tlcr-23-859. Epub 2024 Feb 21.
4
Plant-derived Durvalumab variants show efficient PD-1/PD-L1 blockade and therapeutically favourable FcR binding.植物来源的度伐鲁单抗变体显示出高效的 PD-1/PD-L1 阻断作用和治疗上有利的 FcR 结合。
Plant Biotechnol J. 2024 May;22(5):1224-1237. doi: 10.1111/pbi.14260. Epub 2023 Dec 4.
5
Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer.非小细胞肺癌新辅助免疫治疗疗效预测与监测的进展
Front Oncol. 2023 May 17;13:1145128. doi: 10.3389/fonc.2023.1145128. eCollection 2023.
6
Emerging phagocytosis checkpoints in cancer immunotherapy.癌症免疫治疗中的新兴吞噬检查点。
Signal Transduct Target Ther. 2023 Mar 7;8(1):104. doi: 10.1038/s41392-023-01365-z.
7
Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort.使用扩展队列更新接受免疫检查点抑制剂治疗的头颈部鳞状细胞癌患者的预后生存模型。
BMC Cancer. 2022 Jul 14;22(1):767. doi: 10.1186/s12885-022-09809-5.
8
Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy.免疫检查点抑制剂治疗下超进展性疾病中的免疫细胞。
Cells. 2022 May 27;11(11):1758. doi: 10.3390/cells11111758.
9
Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.免疫治疗下的超进展：一种新的免疫治疗反应形式？——一篇叙述性文献综述
Transl Lung Cancer Res. 2021 Jul;10(7):3276-3291. doi: 10.21037/tlcr-21-575.
10
Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.肿瘤内滤泡调节性 T 细胞抑制抗 PD-1 治疗效果。
Nat Immunol. 2021 Aug;22(8):1052-1063. doi: 10.1038/s41590-021-00958-6. Epub 2021 Jun 24.

本文引用的文献

1
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.Fc 工程化抗 CD40 抗体的毒性通过瘤内注射被消除，导致持久的抗肿瘤免疫。
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):11048-11053. doi: 10.1073/pnas.1810566115. Epub 2018 Oct 8.
2
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.抗体 Fc/FcR 相互作用在巨噬细胞中作为 PD-1/PD-L1 阻断后非小细胞肺癌发生超进展性疾病的机制。
Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.
3
Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.肿瘤表达的PD-1的阻断促进肺癌生长。
Oncoimmunology. 2018 Jan 29;7(4):e1408747. doi: 10.1080/2162402X.2017.1408747. eCollection 2018.
4
Signaling by Antibodies: Recent Progress.抗体信号传导：最新进展
Annu Rev Immunol. 2017 Apr 26;35:285-311. doi: 10.1146/annurev-immunol-051116-052433.
5
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.Fcγ 受体调节靶向 PD-1/PD-L1 轴的抗体的抗肿瘤活性。
Cancer Cell. 2015 Sep 14;28(3):285-95. doi: 10.1016/j.ccell.2015.08.004.